Transaction in own shares (1205175)
June 07 2021 - 12:08PM
UK Regulatory
Arix Bioscience PLC (ARIX)
Transaction in own shares
07-Jun-2021 / 17:07 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Transaction in own shares
LONDON, 07 June 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company
focused on investing in and building breakthrough biotech companies, today announces that it purchased the following
number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as
part of a buyback programme announced on 22 March 2021.
Date of purchase 07 June 2021
Aggregate number of shares purchased 20,000
Highest price paid per share 177.00p
Lowest price paid per share 177.00p
Average price paid per share 177.00p
Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have
131,826,800 ordinary shares of 0.001 pence each in issue (excluding
3,782,853 ordinary shares of 0.001 pence each held in treasury).
This number represents the total voting rights in Arix and may be
used by shareholders as the denominator for the calculations by
which they can determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No.
596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018), the schedule below contains detailed
information of the individual trades made by Jefferies
International Limited as part of the buyback programme.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number
07/06/2021 16:35:00 20,000 177.00 London Stock Exchange 00244951341TRLO1 -----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: POS
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares
Sequence No.: 109798
EQS News ID: 1205175
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1205175&application_name=news
(END) Dow Jones Newswires
June 07, 2021 12:08 ET (16:08 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024